(Reuters) - GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The decision is the latest ...

A month before it was set to take the stand in the highly anticipated first Zantac-related trial, GSK scratched ... Last month, GSK saw a win in a key class-action suit in Canada after the British ...

GSK and Boehringer Ingelheim are the only defendants in the trial, after other ... and does not contain ranitidine. The companies notched a significant win in 2022 when a judge dismissed about ...

GSK Plc convinced an Illinois jury that the former heartburn drug Zantac was not liable for a woman’s colorectal cancer in a second trial win for the British drugmaker. It comes just over two ...

GSK has won its latest trial over whether its former best-selling drug caused ... from a contaminant known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...